The Week in Review: China Life Science Convergence

The world of China life science is “ascendant,” according to Greg B. Scott, Executive Editor of ChinaBio® Today in a presentation; ChinaBio® has formed a China domestic company, ChinaBio Accelerator (Shanghai), to help US life science companies establish operations in China; Pharmaron completed its acquisition of fellow CRO Bridge Laboratories China; bioMerieux acquired Meikang Biotech, a China company also involved in rapid test manufacturing; WuXi AppTec and QIAGEN partnered up to develop molecular biomarkers; Beike Biotech received a $1.8 million grant to conduct a clinical trial using umbilical cord stem cells; Mindray Medical (迈瑞医疗国际有限公司) expects 2009 financial results to beat analysts' estimates; Sinovac Biotech (NSDQ: SVA) (北京科兴生物制品有限公司) received an 8.6 million dose order for its H1N1 vaccine, Panflu.1; Jiangbo Pharma said its oral Osteomyelitis treatment, was included in the 2009 Insurance Directory; Invida Group will launch three dermatological brands in China; China Sky One Medical's (中国天字一号医药公司) heart disease diagnositc kit was designated a National Innovation Project; and Suven Life Sciences was granted two patents in China for new chemical entities. More details... Stock Symbol: (Euronext: BIM) (NYSE: WX) (NYSE: MR) (OTCBB: JGBO) (NSDQ: CSKI)